Epigral Ltd (IN:EPIGRAL)
:EPIGRAL
Want to see IN:EPIGRAL full AI Analyst Report?
EPIGRAL Stock Chart & Stats
₹1244.30
-₹4.30(-0.24%)
At close: 4:00 PM EST
₹1244.30
-₹4.30(-0.24%)
Day’s Range― - ―
52-Week Range₹806.20 - ₹2,114.30
Previous CloseN/A
Volume42.70K
Average Volume (3M)1.86K
Market Cap
₹47.99B
Enterprise Value₹55.75B
Total Cash (Recent Filing)₹485.70M
Total Debt (Recent Filing)₹5.37B
Price to Earnings (P/E)14.5
Beta1.53
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)93.51
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.38
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)93.8
Revenue Forecast (FY)₹33.92B
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthLeverage has fallen to roughly 0.26x equity and equity has grown, giving the company materially more financial flexibility. Lower debt reduces interest expense vulnerability and supports capital allocation (capex, M&A, dividends) during cyclical downturns, improving multi-month resilience.
Sustainable ProfitabilityMargins and a roughly 15% ROE remain healthy for a chemicals firm, indicating structural pricing power or cost advantages. Durable margin levels support internal funding for maintenance capex and R&D, helping preserve competitive position and returns over the coming quarters.
Track Record Of Revenue ExpansionHistorical multi-year revenue expansion shows the business has scaled products and distribution successfully. That track record suggests an established customer base and go-to-market capabilities that can enable a return to growth once near-term headwinds abate, supporting medium-term recovery.
Bears Say
Weak Cash GenerationFree cash flow slipping to negative and operating cash covering only about half of EBITDA signals working-capital strain or lumpy investments. Persistent weak cash conversion limits self-funding, raises financing reliance, and constrains durable capital allocation choices over the next several quarters.
Revenue And Margin SofteningRecent flat revenue and compressed gross/operating margins point to weaker demand or higher input costs. If structural, this reduces sustainable profit levels and weakens the company’s ability to generate consistent earnings and reinvest, increasing medium-term operational risk.
Earnings And Growth VolatilityNegative EPS growth and volatile revenue metrics highlight earnings unpredictability. For a chemical producer, such volatility hampers planning, may raise working-capital needs and increases the probability of swings in credit or funding costs, all of which challenge steady long-term execution.
Epigral Ltd News
EPIGRAL FAQ
What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹806.20 and its highest was ₹2114.30 in the past 12 months.
What is Epigral Ltd’s market cap?
Epigral Ltd’s market cap is ₹47.99B.
When is Epigral Ltd’s upcoming earnings report date?
Epigral Ltd’s upcoming earnings report date is Aug 03, 2026 which is in 53 days.
How were Epigral Ltd’s earnings last quarter?
Epigral Ltd released its earnings results on May 02, 2026. The company reported ₹19 earnings per share for the quarter, beating the consensus estimate of ₹14.3 by ₹4.7.
Is Epigral Ltd overvalued?
According to Wall Street analysts Epigral Ltd’s price is currently Overvalued.
Does Epigral Ltd pay dividends?
Epigral Ltd pays a Semiannually dividend of ₹5 which represents an annual dividend yield of 0.46%. See more information on Epigral Ltd dividends here
What is Epigral Ltd’s EPS estimate?
Epigral Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Epigral Ltd have?
Epigral Ltd has 43,141,340 shares outstanding.
What happened to Epigral Ltd’s price movement after its last earnings report?
Epigral Ltd reported an EPS of ₹19 in its last earnings report, beating expectations of ₹14.3. Following the earnings report the stock price went up 0.894%.
Which hedge fund is a major shareholder of Epigral Ltd?
Currently, no hedge funds are holding shares in IN:EPIGRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Epigral Ltd
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash. Additionally, the company is involved in the trading of agrochemical products. Epigral caters to an extensive list of industries, including CPVC pipes and fittings, wind energy, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soaps and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. Incorporated in 2007 and based in Ahmedabad, India, the company was formerly known as Meghmani Finechem Limited until it adopted the name Epigral Limited in August 2023.
Technical Analysis
Gufic Biosciences Limited
―
Marksans Pharma Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Supriya Lifescience Limited
―